Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (October 2025)
23 slides from Sona Nanotech's investor presentation, October 2025
Slide 1: Sona's Targeted Hyperthermia Therapy: A Novel Nanomedical Immunomodulator
Sona’s Targeted Hyperthermia Therapy: A Novel Nanomedical Immunomodulator Priming the Immune System to Enable Immunotherapy Demonstrated Safety, Tolerability and Compelling Efficacy In Our First-in-human Study October 2025 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses activities this presentation due to risks and uncertainties affecting Sona or developments tha
Slide 3: Investment Highlights
Investment Highlights Gentle but powerful therapy - kills cancer cells selectively and activates the immune system • Heating tumors from the inside out to elicit neo-antigens that engage the immune system and enhance immunotherapy drug response rates Compelling human efficacy, safety and tolerabilit
Slide 4: Immunotherapy Checkpoint Inhibitors Release The Brakes For The Immune System
Immunotherapy Checkpoint Inhibitors Release Immunotherapy has provided a ‘step The Brakes For The Immune System To More change’ in cancer treatment Readily Recognize and Attack Cancer However, immunotherapy still has: ➢Limited response rates ➢ Typical response rate is 15-30% ➢Toxicity ➢ Severe toxic
Slide 5: Pembrolizumab's Five-Year Overall Survival And Average Response Rates Were Just 34% and 21%
For Instance, Pembrolizumab’s Five-Year Overall Survival And Average Response Rates Were Shown To Be Just 34%(1) and 21%(2), Respectively Five Year Overall Survival Rates Immunotherapy Response Rate in Study of 1678 Patients by Cancer Type 100% 80% 60% 40% Average response rate of 21% 20% 0% Colorec
Slide 6: Immunotherapy Response Rates Are Low Because Tumor Antigens Presented Are Too Weak
Immunotherapy Response Rates Are Low Because Tumor Antigens Presented Are Too Weak To Elicit An Immune Response Sources of Immunotherapy Resistance More of a good thing isn’t 1. Weak tumor antigen expression necessarily better: 2. Upregulation of immune-checkpoint Addressing a weak antigen tumor mol
Slide 7: Sona's THT Heats Tumors Gently With Near-infrared-activated GNRs
Sona’s THT Heats Tumors Gently With Near-infrared-activated GNRs Causing Apoptotic Cancer Cell Death* Revealing Neo-antigens and Engaging the Immune System *Apoptotic Cell Death: When a cell actively self- destructs in a controlled manner. In so doing, the dying cells become more "visible" to immune
Slide 8: Sona's Gold Nanorods Are Toxin-free And Provide Fastest Thermal Conversion
Sona’s Gold Nanorods Are Toxin-free And Provide Fastest Thermal Conversion Within Tumors For A ~5-10 Minute Clinical Treatment Sona’s Gold Nanorod’s (“GNR”) Advantages Highly functional: • Optimal nanoparticle for thermal conversion • Can be ‘tuned’ to react to set wavelengths • Can be conjugated to
Slide 9: Preclinical Animal Studies Demonstrated THT's Ability To Make Immunotherapies Work In 'Cold' Tumors
Preclinical Animal Studies Demonstrated THT’s Ability To Make Immunotherapies Work In ‘Cold’ Tumors Colorectal Cancer Study Cohort Averages 700 600 Tumor Volume (mm3) 500 Immunotherapy 400 1st Cohort Avg without THT 2nd Cohort Avg 300 PD1 Cohort Avg 200 100 Immunotherapy with THT 0 -6 -3 0 1 2 3 4 7
Slide 10: 1st Human Study Protocol Aimed To Show THT's Power As A Mono-therapy
1st Human Study Protocol Aimed To Show THT’s Power As A Mono- therapy In An Immunotherapy-resistant Solid Cancer Key Protocol Elements Key Enrolment Criteria o Two applications of THT (day one and day o Up to 10 participants with stable or eight), to create hyperthermia in tumors, up progressive cut
Slide 11: THT's First-in-human Clinical Study Results
THT’s First-in-human Clinical Study Results Objective was to generate data and insights in four areas: • Safety: Only one serious adverse event but unrelated to therapy • Tolerability: No drop-outs and no refusals to second treatment • Design factors: 16+ technique and device enhancements identified
Slide 12: THT 1st Clinical Study – Treatment Example
THT 1st Clinical Study – Treatment Example Step 1 - Intertumoral injection of Step 2 - Initiate and monitor 0.5ml GNR solution hyperthermia for 5-10 minutes 12
Slide 13: THT 1st Clinical Study Results: Efficacy
THT 1st Clinical Study Results: Efficacy New Patient Stage Day 15 Biopsy Day 28 Biopsy Data 1 IV 100% response No longer cancerous 2 IV 100% response No longer cancerous 3 IV No response n/a 4 IV No response n/a 5 III 100% response No longer cancerous 6 TBD 100% response No longer cancerous 7 TBD 10
Slide 14: Patient #9
Patient #9 Initial screening After second THT assessment treatment 14
Slide 15: Patient #6
Patient #6 Day 16 biopsy Day 1 – confirmed Day 8 – second Day 29 a scab melanoma tumor confirms tumor treatment given remains negative for melanoma 15
Slide 16: Patient #1
Patient #1 Day 1 Day 8 Day 15 Day 29 Day 15 biopsy confirms tumor negative for melanoma 16
Slide 17: THT 1st Clinical Trial – Histological Readouts Post-treatment Still To Come
THT 1st Clinical Trial – Histological Readouts Post-treatment Still To Come Change in Immune Infiltrates (Preclinical Mouse Model) CD3 IHC stain Note: Brown staining represents CD3+ cells. Scale bar represents 50 µm. Efficacy in humans will be further assessed by the extent immune infiltrates as evi
Slide 18: Sona's THT Therapy is Proprietary And Benefits From IP Protection
Sona’s THT Therapy is Proprietary And Benefits From IP Protection Sona’s Four Sources of IP Advantage Patents: THT Theragnostic concept: • Method for Manufacture of Biocompatible Gold Nanorods • Leveraging both the biocompatibility and • Issued: USA, Canada and South Korea. Pending: PCT, EU. functio
Slide 19: Next Steps - Leveraging Biocompatible GNR Platform To Develop Further Applications
Next Steps - Sona Is Leveraging On Its Uniquely Biocompatible GNR Platform Technology To Develop Further Applications Sona’s Product Pipeline – By Stage Of Development Discovery and Pre-clinical Early Feasibility Pilot Study Pivotal Study Concept Design Studies (~10 patients) (15-45 patients) (100’s
Slide 20: A Team That Hits Above The Company's Weight
A Team That Hits Above The Company’s Weight Board Mark Lievonen Walter Strapps PhD Neil Fraser Jim Megann Wayne Myles, KC Len Pagliaro, PhD Chairman Director Director Director Director Director o Led vaccine maker Sanofi- o CEO of Khosla Ventures o Led Medtronic Canada for o 25 years of experience i
Slide 21: Next Steps
Next Steps 1. Further assess full data set and conduct histology analysis 2. Monitor study patients for further evidence of abscopal effect 3. Pilot Study • Refined treatment Health Canada's assessment of risk considers factors such as the • Data expected to qualify for most regulators nanoparticle'
Slide 22: Capitalization Table
Capitalization Table As of October 20, 2025 Market Capitalization Ownership Share Price C$0.77 Board and Market Cap. C$85M 15% Management 52 Week High/Low $0.91/$0.24 Capital Structure Issued & Outstanding 112.5M Options 7.2M Warrants 2.6M Public 85% 22
Slide 23: Thank you
Thank you BIOCOMPATIBLE GNR David Regan david@sonanano.com GOLD NANOROD TECHNOLOGY CEO +1 902 448 1416 Sona Nanotech Inc. sonanano.com 23 CSE: SONA | OTCQB: SNANF